and Mr. Thompson serve as Class I Directors with a term of office expiring at the 2015 Annual Meeting.
Joseph L. Bower
Dr. Bower joined the Board of Directors of Anika Therapeutics in February 1993 and has served as lead director since April 2005. Since 2008, he has been the Baker Foundation Professor of Business Administration at Harvard Business School, and prior to 2008, he was the Donald Kirk David Professor of Business Administration. Dr. Bower also serves as a director of Loews Inc., the New America High Income Fund and Sonesta International Hotels Corporation.
During the past five years, Dr. Bower also served as a director of the TH Lee Putnam EOP Fund. Dr.
Bower brings to the Board more than three decades of experience in corporate governance and management, during which he has written books and taught these subjects at the Harvard Business School.
has consulted with numerous organizations on problems of strategy and organizational development, including strategic planning and succession planning.
As a result, we believe he
is well suited for his
roles as lead director and as chair of our Compensation Committee.
Dr. Bower serves as the Lead Director of the Company. Separating the Lead Director role and the Chief Executive Officer role allows our Chief Executive Officer to focus on strategic management of the day-to-day business of the Company, while allowing the Lead Director to focus on leading our Board in its fundamental role of providing advice to and independent oversight of management.
Our Board recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our Lead Director, particularly as the Board's oversight responsibilities continue to grow.
The current members of the Audit Committee
are Mr. Land, as Chairperson, Dr. Bower, and Mr. Moran.
Messrs. Land and Moran and Dr. Bower served on the Audit Committee throughout 2012.
The current members of the Compensation Committee are Dr. Bower, as Chairperson, Mr. Thompson, and Mr. Wheeler, each of whom is independent for purposes of NASDAQ listing standards and the SEC
Messrs. Thompson and Wheeler and Dr. Bower served on the Compensation Committee throughout 2012.
Joseph L. Bower
This amount includes (i) 8,284 shares of restricted stock units and 6,115 shares subject to stock options and stock appreciation rights that are exercisable within 60 days of March 31, 2013, and (ii) 2,000 shares owned by Dr. Bower's
The shares of restricted stock units are unvested and will be fully vested if the director leaves the Company in good standing. On December 26, 2012, 100,000 shares previously owned by Dr. Bower
were transferred to two multigenerational trusts for the benefit of Dr. Bower's
retains no control over the trusts, and disclaims any beneficial ownership of these shares.